Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy B London

Showing results (71-80 of 230) with videos related to

Pageof 23
Sort By:
Pediatric Blood & Cancer|October 13, 2011
Clinical significance of NTRK family gene expression in neuroblastomasJennifer E Light, Hiroshi Koyama, Jane E Minturn, et al.
Pediatric Blood & Cancer|January 6, 2010
Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology GroupPamela Bensimhon, Judith G Villablanca, Leonard S Sender, et al.
Cancer Letters|July 19, 2005
The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectivesWendy B London, Luca Boni, Thorsten Simon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2011
Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group studyJulie R Park, Jeffrey R Scott, Clinton F Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group studyWendy B London, Christopher N Frantz, Laura A Campbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2009
Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group studyKatherine K Matthay, C Patrick Reynolds, Robert C Seeger, et al.
Scientific Reports|November 22, 2023
Monte Carlo based dosimetry of extraoral photobiomodulation for prevention of oral mucositisAnna N Yaroslavsky, Tyler W Iorizzo, Amy F Juliano, et al.
Pediatric Blood & Cancer|August 23, 2012
Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology GroupCameron K Tebbi, Nancy P Mendenhall, Wendy B London, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2007
Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's diseaseCameron K Tebbi, Wendy B London, Debra Friedman, et al.
Pediatric Blood & Cancer|September 17, 2013
Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group projectYaël P Mossé, Rebecca J Deyell, Frank Berthold, et al.
Pageof 23

Showing results (71-80 of 230) with videos related to

Sort By:
Pageof 23
Pediatric Blood & Cancer|October 13, 2011
Clinical significance of NTRK family gene expression in neuroblastomasJennifer E Light, Hiroshi Koyama, Jane E Minturn, et al.
Pediatric Blood & Cancer|January 6, 2010
Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology GroupPamela Bensimhon, Judith G Villablanca, Leonard S Sender, et al.
Cancer Letters|July 19, 2005
The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectivesWendy B London, Luca Boni, Thorsten Simon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2011
Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group studyJulie R Park, Jeffrey R Scott, Clinton F Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group studyWendy B London, Christopher N Frantz, Laura A Campbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2009
Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group studyKatherine K Matthay, C Patrick Reynolds, Robert C Seeger, et al.
Scientific Reports|November 22, 2023
Monte Carlo based dosimetry of extraoral photobiomodulation for prevention of oral mucositisAnna N Yaroslavsky, Tyler W Iorizzo, Amy F Juliano, et al.
Pediatric Blood & Cancer|August 23, 2012
Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology GroupCameron K Tebbi, Nancy P Mendenhall, Wendy B London, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2007
Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's diseaseCameron K Tebbi, Wendy B London, Debra Friedman, et al.
Pediatric Blood & Cancer|September 17, 2013
Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group projectYaël P Mossé, Rebecca J Deyell, Frank Berthold, et al.
Pageof 23